Weekly insulin shot could replace daily injections for diabetes
NCT ID NCT07658417
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how well a new once-weekly insulin, called insulin icodec, works for people with type 2 diabetes who are switching from a daily insulin. Researchers will track blood sugar control, treatment satisfaction, and how well patients stick to the new regimen over about 30 weeks. The study involves 216 adults in China and aims to see if the weekly shot is a practical and effective option in real-world settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
insulin icodec (a once-weekly insulin injection)
What this could lead to
If successful, this could show that a once-weekly insulin is as effective as daily insulin for managing type 2 diabetes, potentially simplifying treatment and improving quality of life.
What could go wrong
This is an early real-world study with only 216 participants and no comparison group, so results may not apply broadly. There is also a risk of hypoglycemia or other side effects with any insulin.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS (TYPE 2) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Hospital
Beijing, Beijing Municipality, 100730, China
-
Gansu Provincial People's Hospital
Lanzhou, Gansu, 730000, China
-
Hebei PetroChina Central Hospital
Langfang, Hebi, 065099, China
-
Heilongjiang Provincial Hospital
Harbin, Heilongjiang, 150036, China
-
NIS-Huai'an First People's Hospital-Endocrinology
Huai'an, Jiangsu, 223300, China
-
NIS-Nanjing Jiangning Hospital-Endocrinology
Nanjing, Jiangsu, 211199, China
-
Shandong Provincial Hospital
Jinan, Shandong, 250098, China
-
Shiyan City People's Hospital
Shiyan, Hubei, 442099, China
-
The Fifth People's Hospital of Shenyang
Shenyang, Liaoning, 110023, China
-
The First Affiliated Hospital of Xinjiang Medical University
Urumuqi, Xinjiang, 830054, China
-
The People's Hospital of JiangMen
Jiangmen, Guangdong, 529020, China
-
The Second Affiliated Hospital of Chongqing Medical University-Endocrinology
Chongqing, Chongqing Municipality, 400010, China
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China
-
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215004, China
-
Tongren Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200050, China